Summary:
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover, Multicenter Clinical Study to Assess the Efficacy and Safety of Once Daily Administration of Lupin Tiotropium Bromide Inhalation Powder Compared to SPIRIVA HANDIHALER and Placebo in Patients with COPD including a 12-week Open-Label Extension to Assess Inhaler Robustness.
Qualified Participants Must:
• Be Male or Female patients 40 years of age and older, inclusive as of the screening visit (visit 1)
• Have a diagnosis of COPD
•
Be a current smoker or non-smoker with a minimum 10 pack-years of historical use, the equivalent of one pack per day for 10 years
•
If female of childbearing potential and committed to consistent and correct use of an acceptable method of birth control
Qualified Participants May Receive:
Can get compensated up to $1,150, free treatment and doctor consultations with 24hr emergency phone line.